bismuth-subgallate and Peptic-Ulcer

bismuth-subgallate has been researched along with Peptic-Ulcer* in 1 studies

Other Studies

1 other study(ies) available for bismuth-subgallate and Peptic-Ulcer

ArticleYear
Bismuth absorption from 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease.
    Scandinavian journal of gastroenterology, 1992, Volume: 27, Issue:4

    The absorption of bismuth from five 205Bi-labelled pharmaceutically used bismuth compounds was studied in man. From single oral doses of all compounds under investigation only less than 0.1% bismuth was absorbed and excreted with the urine. A significantly higher absorption was observed from the colloidal bismuth subcitrate (0.042% of the dose) and the basic bismuth gallate (0.038%) than from the basic bismuth salicylate, nitrate, and aluminate (0.005-0.002%). No retention of bismuth in the whole body was found from the single dose experiment. The biologic fast-term half-lives of absorbed bismuth were calculated to be 0.12 and 1.5 days.

    Topics: Adult; Aluminum; Anti-Ulcer Agents; Biological Availability; Bismuth; Female; Gallic Acid; Humans; Intestinal Absorption; Male; Middle Aged; Nitrates; Organometallic Compounds; Peptic Ulcer; Radioisotopes

1992